Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA‐SWITCH): a randomized, double‐blind, double‐dummy, active‐controlled 26‐week trial

@inproceedings{Bailey2016EfficacyAS,
  title={Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA‐SWITCH): a randomized, double‐blind, double‐dummy, active‐controlled 26‐week trial},
  author={Timothy Silleck Bailey and R{\'o}bert T{\'a}kacs and Francisco J Tinahones and Paturi Vishnupriya Rao and George Tsoukas and A. Bloch Thomsen and Margit Staum Kaltoft and Maximo Maislos},
  booktitle={Diabetes, obesity & metabolism},
  year={2016}
}
AIMS To confirm superiority on glycaemic control by switching from sitagliptin to liraglutide 1.8 mg/d versus continued sitagliptin. MATERIALS AND METHODS A randomized, multicentre, double-blind, double-dummy, active-controlled trial across 86 office- or hospital-based sites in North America, Europe and Asia. Subjects with type 2 diabetes who had inadequate glycaemic control (glycated haemoglobin [HbA1c] 7.5-9.5% on sitagliptin (100 mg/d) and metformin (≥1500 mg daily) for ≥90 days were… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-6 OF 6 CITATIONS

Ertugliflozin Compared to Other Anti-hyperglycemic Agents as Monotherapy and Add-on Therapy in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis

  • Diabetes therapy : research, treatment and education of diabetes and related disorders
  • 2019
VIEW 4 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 23 REFERENCES

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

  • The New England journal of medicine
  • 2016
VIEW 1 EXCERPT

Once-daily liraglutide vs. lixisenatide as add-on to metformin in type 2 diabetes: a 26-week randomised controlled clinical trial (Abstract 75)

M Nauck, M Rizzo, V Pirags
  • Diabetologia. 2015;58(suppl 1):1–607
  • 2015

Victoza–European summary of product characteristics

AS NovoNordisk
  • http://www.ema.europa.eu/docs/en_GB/document_library/ EPAR_-_Product_Information/human/001026/WC500050017.pdf. Accessed August
  • 2015
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…